4Kuti JL, Moss KM, Nicolau DP, et al.Empiric treatment of multidrug-resistant burkholderia cepacia lung exacerba- tion in a patient with cystic fibrosis: application of phar- macodynamic concepts to meropenem therapy[J]. Phar- macotherapy, 2004,24( 11 ) : 1 641.
3BrysonHM,BrogdenRN. Piperacillin/tazobactarm. Are view of its antibacterial activity, pharmacokinetic properties and thera- peutic potential[J]. Drugs, 1994,47: 506.
4Valerie Augey et al. High-performance liqid chromatographic of tazobactam and piperacilin in human plasma and urine Jourmal of chromatographic B. 1996,682,125-136.
5Arzuaga A. Quantitation and stability of piperacilin and tazobactam in plasma'and ultrafiltrate from patient undergping continuous venovenous hemofiltration by HPLC biomed. Chromatogr. 2005,19(8) :570-8.
8Zhanel GG,Ennis K,Vercaigne L,et al.A critical review of the fluoroquinolones:focus on respiratory tract infections[J].Drugs,2002,62(1):13-59.
9Fish DN,Chow AT.The clinical pharmacikinetics of levofloxacin[J].Clin Pharmacokinet,1997,32(2):101-119.
10Rebuck JA,Fish DN,Abraham E.Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit[J].Pharmacotherapy,2002,22(10):1216-1122.
8Ambrose PG, Bhavnani SM, Jones RN, et al. Use of Pharmacokenetics Pharmacodynamics(PK-PD) and Monte Carlo Simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae [ M ]// Interscience Conference on Antimicrubial Agents and Chemotherapy. Washington: ICAAC,2004.
9Pottumarthy S, Yu Y, Sader HS, et al. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta- lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta- lactams[J]. Diagn Microbiol Infect Dis,2005,53(2):131-141.
10Craig WA. Pharmacokinetic/pharmacodynamic parame- ters: rationale for antibacterial dosing of mice and men[J]. Clin Infect Dis,1998,26(1):l-10.
